Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04578496
Other study ID # CUV037
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date July 11, 2011
Est. completion date February 27, 2014

Study information

Verified date November 2020
Source Clinuvel Pharmaceuticals Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main objectives of the study were to evaluate the safety and tolerability of afamelanotide by measuring treatment emergent adverse events (AEs) and to determine whether afamelanotide can improve the quality of life of EPP patients.


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date February 27, 2014
Est. primary completion date February 27, 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - male or female subjects with a positive diagnosis of EPP who successfully completed the CUV017 or CUV029 studies; - aged 18-75 years (inclusive); - provide written informed patient consent prior to the performance of any study-specific procedure. Exclusion Criteria: - any serious adverse event considered to be related to afamelanotide or the polymer contained in the implant; - any allergy to lignocaine or other local anaesthetic to be used during the administration of the study medication; - EPP patients with significant hepatic involvement; - personal history of melanoma or dysplastic nevus syndrome; - current Bowen's disease, basal cell carcinoma, squamous cell carcinoma, or other malignant or premalignant skin lesions; - any evidence of clinically significant organ dysfunction or any clinically significant deviation from normal in the clinical or laboratory determinations; - acute history of drug or alcohol abuse (in the last 12 months); - female who is pregnant (confirmed by positive serum ß-Human Chorionic Gonadotropin (HCG) pregnancy test prior to baseline) or lactating; - females of child-bearing potential (pre-menopausal, not surgically sterile) not using adequate contraceptive measures (i.e. oral contraceptives, diaphragm plus spermicide, intrauterine device); - sexually active men with partners of child-bearing potential not using barrier contraception during the trial and for a period of three months thereafter; - participation in a clinical trial for an investigational agent within 30 days prior to the screening visit; - prior and concomitant therapy with medications which may interfere with the objectives of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Afamelanotide


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Clinuvel Pharmaceuticals Limited

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Quality of Life Measured Using the EPP-quality of Life Questionnaire (EPP-QoL). The EPP-QoL is presented as 15 questions aiming at measuring how the condition has affected the patient over the last 2 months. Each question is answered on a categorical scale. The maximum score is calculated by summing the score of each question resulting in a maximum of 100 and a minimum of 0. The higher the score, the better the quality of life. Baseline, Day 60, Day 120, Day 180 or early termination (ET) (if applicable)
Primary Change in Quality of Life Measured Using the Dermatology Life Quality Index Questionnaire (DLQI) The DLQI questionnaire consists of 10 questions, each answered on a categorical scale. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. Baseline, Day 60, Day 120, Day 180 or early termination (ET) (if applicable)
See also
  Status Clinical Trial Phase
Completed NCT00979745 - Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP) Phase 3
Active, not recruiting NCT05308472 - Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP Phase 2
Completed NCT00004831 - Study of Cysteine Hydrochloride for Erythropoietic Protoporphyria N/A
Completed NCT05572125 - Iron Therapy in Erythropoietic Protoporphyria
Completed NCT01605136 - Phase III Confirmatory Study in Erythropoietic Protoporphyria Phase 3
Completed NCT01422915 - Sorbent Therapy of the Cutaneous Porphyrias Phase 2/Phase 3
Completed NCT04053270 - Multicentre Phase III Erythropoietic Protoporphyria Study Phase 3
Completed NCT00004940 - Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria Phase 3
Recruiting NCT06388642 - Pharmacokinetics of Afamelanotide in EPP Patients Phase 1/Phase 2
Recruiting NCT05020184 - Effect of Oral Cimetidine in the Protoporphyrias Phase 2
Completed NCT01688895 - Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact
Recruiting NCT00206869 - Does Exercise and Heat Increase the Lightsensibility in Patients With Erythropoietic Protoporphyria N/A
Recruiting NCT05780840 - Protection Against Visible Light by Dihydroxyacetone in Erythropoietic Protoporphyria N/A
Completed NCT02979249 - Oral Iron for Erythropoietic Protoporphyrias N/A
Enrolling by invitation NCT05883748 - Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP Phase 2/Phase 3
Completed NCT01097044 - Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP) Phase 2
Completed NCT03682731 - Light Exposure Patterns and Symptoms Among Patients With Erythropoietic Protoporphyria